Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — JMP Securities Life Sciences Conference 2022
25 slides from Sutro Biopharma's conference presentation, Jun 16, 2022
Slide 1: JMP Securities Life Sciences Conference
JMP Securities Life Sciences Conference June 2022 Sutro Biopharma NASDAQ: STRO 1 NON CONFIDENTIAL
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state
Slide 3: Drug Discovery Platform Enables the Potential for Best-in-Class Molecules
Drug Discovery Platform Enables the Potential for Best-in-Class Molecules Precise novel design to enhance potential efficacy and safety across multiple modalities and targets Cytokine Derivative Conjugated Antibody Bispecific Antibody Prodrug Cytokine ADC or ISAC iADC Modality Bispecific ADC Immune
Slide 4: Robust Pipeline through Wholly-Owned and Partnered Programs
Robust Pipeline through Wholly-Owned and Partnered Programs Five product candidates advancing in the clinic and late-stage discovery programs Modality Program Target Indication Discovery Preclinical Phase 1/1b Phase 2/3 Partner Ovarian Cancer Fast Track Designation Ovarian Cancer (bevacizumab combo)
Slide 5: Achievements and Milestones
Achievements and Milestones Clinical data readouts and partnerships provide multiple expected 2022 value drivers for Sutro STRO-002, FolRα ADC STRO-001, CD74 ADC ✓ Greater China deal with Tasly (Dec. 2021) ✓ Greater China deal with BioNova (Oct. 2021) Support BioNova for initiation of clinical devel
Slide 6: FolRα-Targeting ADC
STRO 002 FolRα-Targeting ADC Potential Best-in-Class ADC for Ovarian and Endometrial Cancers 6 NON CONFIDENTIAL
Slide 7: Highly optimized ADC designed to drive efficient tumor responses
Highly optimized ADC designed to drive efficient tumor responses STRO 002 across a broad range of target antigen levels 1 FolRα STRO-002 is a homogeneous antibody drug conjugate (ADC) with a drug-antibody ratio (DAR) of 4, targeting folate-receptor alpha (FolRα) Y180 1 FolRα is overexpressed in cert
Slide 8: Phase 1 Study in Patients with Advanced Ovarian Cancer
Phase 1 Study in Patients with Advanced Ovarian Cancer STRO 002 Two-part design to explore safety, anti-tumor activity, dosing, and FolRα enrichment strategy Part 1: Dose-Escalation Cohort Part 2: Dose-Expansion Cohort Protocol Inclusive of all FolRα expression levels; tissue samples Inclusive of al
Slide 9: Patient Characteristics in Dose Expansion Cohort
Patient Characteristics in Dose Expansion Cohort STRO 002 Dose Expansion Interim data for dose expansion are as of November 8, 2021 Patient Baseline Characteristics Patient Status as of November 8, 2021 Randomized Dose Levels Total Patients Enrolled Total N=44 Ovarian Cancer 4.3 mg/kg 5.2 mg/kg N=43
Slide 10: Dose Response Demonstrated
Dose Response Demonstrated STRO 002 Dose Expansion Interim data suggest that 5.2 mg/kg starting dose leads to higher response rates Maximum Change in Tumor Target Lesions (N=33) 20% PRu* PRu PRu* PR PR PR PR PRu* PRu* PR PR PR 2 pts had 0% Δ Partial Response -30% Treatment ongoing Starting Dose, Q3W
Slide 11: Objective Response by RECIST v1.1
Objective Response by RECIST v1.1 STRO 002 Dose Expansion 33% ORR rate in all 33 evaluable patients, unenriched for FolRα expression Starting Dose Best Overall Response (BOR) 4.3 mg/kg 5.2 mg/kg All Comers • 47.1% ORR in patients starting at the 5.2 mg/kg dose level Evaluable patients N=16 N=17 N=33
Slide 12: Robust Anti-tumor Activity and Disease Control Demonstrated
Robust Anti-tumor Activity and Disease Control Demonstrated STRO 002 Dose Expansion Responders experienced rapid tumor reduction or a steady deepening of response Change in Sum of Diameters for Target Lesions Over Time (N=33) Starting Dose, Q3W 4.3 mg/kg Change from baseline (%) 5.2 mg/kg Treatment
Slide 13: Encouraging Response Rates and Preliminary Data on Durability
Encouraging Response Rates and Preliminary Data on Durability STRO 002 Dose Expansion Interim data suggest initiating with 5.2 mg/kg followed by a dose adjustment Treatment Duration on Patients with at Least One Dose (N=43) Initial data show partial responses confirmed & Individual patients treated
Slide 14: Platinum-Resistant Ovarian Cancer Patient Treated at 4.3 mg/kg Dose Level
Platinum-Resistant Ovarian Cancer Patient Treated at 4.3 mg/kg Dose Level STRO 002 Dose Expansion Ongoing Partial Response with 72% reduction in tumor burden Initial diagnosis: Stage IV Lateral Abdominal Wall Axillary Lymph Node Inter-aortocaval LN External Iliac LN ovarian cancer, Jan 2020 3 Prior
Slide 15: TPS Identified as Scoring Algorithm Appropriate for STRO-002
TPS Identified as Scoring Algorithm Appropriate for STRO-002 STRO 002 Dose Expansion Exploratory analysis suggests TPS > 25% correlated with higher response ORR by TPS Expression Levels (Total Samples N=33) TPS TPS TPS TPS TPS Overall ≤ 25% > 25% > 50% > 75% Tumor Proportion Score (TPS) ORR 33.3% 12
Slide 16: Emerging Safety Profile is Manageable
Emerging Safety Profile is Manageable – 85.5% of TEAEs were Grade 1-2 STRO 002 Dose Expansion No new safety signals were observed, including the absence of keratopathy Most Common G3+ TEAEs (≥2 Subjects) by Dose 4.3 mg/Kg (N=23) 5.2 mg/Kg (N=20) Total (N=43) Asymptomatic neutropenia Grade 3 Grade 4
Slide 17: Dose Expansion Interim Data Provide Initial Insights on Go-Forward Strategy
Dose Expansion Interim Data Provide Initial Insights on Go-Forward Strategy STRO 002 Dose Expansion Emerging data inform potential starting dose and enrichment strategy Overall Efficacy Dose Response Biomarker Safety Profile Total of 11 confirmed PR (1) 47% ORR (8/17) in Interim data suggest TPS > N
Slide 18: Progressing & Expanding the STRO-002 Franchise
Progressing & Expanding the STRO-002 Franchise STRO 002 Additional clinical studies in ovarian & endometrial, and nonclinical work on other tumor types Ovarian Cancer Combo study with bevacizumab Trial is open and enrolling patients FPI March 2022 Dose-escalation cohort Dose-expansion cohort Registr
Slide 19: CD74-Targeting ADC
STRO 001 CD74-Targeting ADC Potential First and Best-in-Class ADC for B-Cell Malignancies 19 NON CONFIDENTIAL
Slide 20: Potential First-in-Class Molecule for Patients with NHL and MM
Potential First-in-Class Molecule for Patients with NHL and MM STRO 001 Stable CD74 targeting ADC for hematological cancers designed to minimize bystander effects CD74 STRO-001 is a homogeneous antibody drug conjugate (ADC) with a drug-antibody ratio (DAR) of 2, targeting CD74: 1 CD74 is expressed i
Slide 21: STRO-001-BCM1 Study Design and Updates
STRO-001-BCM1 Study Design and Updates STRO 001 Ongoing Phase 1 dose escalation study with NHL update at ASH 2020 STRO-001-BCM1 Dose Escalation Study NHL Cohort Update at ASH 2020 R/R multiple myeloma Cohort A RP2D A total of 21 patients have been treated with (N=30) STRO-001 and 18 patients were ev
Slide 22: ASH 2020 Update in NHL Cohort
ASH 2020 Update in NHL Cohort STRO 001 Heavily pre-treated patient population with 5 median lines of prior therapies Baseline Characteristic (N=21) TEAEs by Grade, Patients With ≥1 Event, n (%) Age, median (range), years 64.5 (21–82) Occurring in ≥15% Grade 1 Grade 2 Grade 3 Grade 4 Time from diagno
Slide 23: Encouraging Interim Treatment Duration and Responses
Encouraging Interim Treatment Duration and Responses STRO 001 Partial responses in two DLBCL patients who had progressed on CAR-T Treatment Duration Responses to STRO-001 SD* Dose Best Doses Duration of Demographics and Level, Prior Therapies PR Diagnosis Responses Received Treatment Individual pati
Slide 24: Financial Overview
Financial Overview Well capitalized through cash and other financial sources $192.1M Projected cash runway into in cash, cash equivalents & 2H 2023(1), marketable securities based on current business plans and as of March 31, 2022 assumptions ~1.6M shares Funding received from our collaborators of o
Slide 25: Experienced Leadership Team
Experienced Leadership Team William Newell, JD Trevor Hallam, PhD Arturo Molina, Ed Albini, MBA Chief Executive Officer and President of Research and MD, MS, FACP Chief Financial Officer Member of the Board of Chief Scientific Officer Chief Medical Officer Directors Jane Chung, RPh Shabbir Anik, PhD
Sutro Biopharma — JMP Securities Life Sciences Conference 2022 on 6ix